source
- AbbVie reports Phase 3 success for lutikizumab in painful skin disease, eyes FDA filing next yearAbbVie announced positive Phase 3 trial results for its experimental IL-1α and IL-1β inhibitor lutikizumab, which is being developed to treat a debilitating skin condition. The study reported impr…
- Sanofi breaks ground on new 36,000-sq-m insulin plant in FrankfurtSanofi has broken ground on a new insulin manufacturing facility at its Frankfurt site, covering roughly 36,000 square meters. The plant is part of the company’s expansion in Germany and is expect…